Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia.
Nahla A M HamedAshraf El GhandourReham Abdel Haleem Abo ElwafaMohamed Rafaat RezkOmar GhallabPublished in: Asian Pacific journal of cancer prevention : APJCP (2023)
Low EZH2 expression is prevalent in Egyptian AML patients subsequently; it is suggested to function as tumor suppressor gene rather than an oncogene. Moreover, EZH2 downregulation is associated with resistance to chemotherapy and high mortality rate.
Keyphrases
- poor prognosis
- long non coding rna
- end stage renal disease
- binding protein
- long noncoding rna
- copy number
- chronic kidney disease
- newly diagnosed
- acute myeloid leukemia
- prognostic factors
- peritoneal dialysis
- signaling pathway
- transcription factor
- cardiovascular events
- patient reported outcomes
- cardiovascular disease
- type diabetes
- acute lymphoblastic leukemia
- locally advanced
- allogeneic hematopoietic stem cell transplantation
- rectal cancer